Background
Results of several studies indicate that breast-conserving surgery (BCS) followed by radiation therapy (RT) is a suitable alternative to mastectomy for the management of early- 
Aim
This report presents the 15-year treatment results of 235 consecutively treated patients with ILC subjected to either mastectomy or BCS.
Material and methods
Two hundred and thirty-five consecutive treated women with unilateral Stage I or II invasive lobular breast carcinoma were treated with axillary dissection and either mastectomy (n = 163) or BCS (n = 72) at the National Institute of Oncology, Budapest between January 1983 and December 1987. Operative decisions regarding breast conservation or mastectomy were based on patient request, but in the eighties mastectomy was often recommended as the surgical treatment of choice. In BCS patients, routine attempts were made to obtain clear surgical margins. Surgery consisted of total resection of the primary tumor with a 1 cm rim of normal tissue. Resection edges were subjected to frozen section and, when the margin was positive wider excision was done. At final pathologic examination, 8 patients had a positive margin. Five of them underwent reexcision and in 3 cases conversion to mastectomy was done. Pathological classification (microscopic tumor size, pT and pN) was done according to the UICC-AJCC TNM System.
Details of adjuvant treatment policy and technique have been described previously. 16 The clinical-pathological and treatment characteristics of the patient population are summarized in Table 1 . Mastectomy patients had generally larger primary. Twenty-two percent of the mastectomy and eight percent of the BCS patients had ER negative tumor. The median RT dose of conserved breast, chest wall or supraclavicular fossa/apex of axilla was 50 Gy (ranges, 44-54 Gy, 42-50 Gy and 44-52 Gy, respectively).
Patients were seen in follow-up at 3-to 6-month intervals until the end of the 5th year, and annually thereafter. Chest X-rays, mammograms, bone scans, abdominal ultrasound examinations and blood tests were performed at least yearly. The local-regional recurrences were scored on all patients, including those who also relapsed at distant sites. Malignancy of local-regional recurrence and new primary tumor was proved by histologic or cytologic examination in every case. Distant metastases were defined as a recurrence outside the target volume. Thus, a supraclavicular recurrence was recorded as a regional -not distant -treatment failure. The median follow-up time for surviving patients was 181 months (range, 151-210 months).
Survival times were calculated as the time from surgery to the date of the event or the end of the follow-up period. Patients lost to follow-up were inserted in the analysis as censored data. The following end points were studied: any death for overall survival; death from breast cancer for breast cancer- specific survival; chest wall or ipsilateral in-breast recurrence for local recurrence-free survival; local or regional recurrence, whichever came first, for locoregional recurrence-free survival; distant metastasis for distant disease-free survival. The actuarial rate of survival was estimated by the Kaplan-Meier method. 17 Differences in survival between study groups were compared using the log-rank test. In univariate and multivariate analysis the Cox's regression model was used. 18 Relative risk (RR) and associated confidence intervals (CI) were calculated from the proportional regression coefficients. Statistical differences in proportions and means were assessed by 2-sample t-test. All tests were performed at the 0.05 level of significance.
Results

All patients
Three (1.3%) patients were lost to follow-up between 72 and 120 months. During the follow-up period 114 (48.5%) patients died, and 121 of them (51.5%) were still alive. 
Surgical treatment groups
The survival outcomes after 5, 10, and 15 years are shown in Table 2 . The 15-year local recurrence-free survival for mastectomy or BCS patients was 89 and 77%, respectively (RR: 2.03; p = 0.05). There were no significant differences between the two groups with regard to locoregional recurrence-free, distant recurrence-free or breast cancer-specific survival. However, a significant trend was seen toward a better overall survival in the BCS group (p = 0.0122). It is to be noted that the incidence of intercurrent death was 15% in the mastectomy and 12% in the BCS group, and three deaths caused by other malignancy occurred in the mastectomy group.
4.3.
Subgroups by radiotherapy Table 3 shows the actuarial local recurrence rate after 5, 10 and 15 years in the two surgical groups by radiotherapy. The 15-year local recurrence rate for BCS patients without or with irradiation was 53% and 10%, respectively (RR: 0.10; p < 0.0001).
The median time to local failure for irradiated breasts was 87.5 months (2 of 4 relapses occurred after 10 years), as compared to 38.5 months for nonirradiated breasts (p = 0.0238). The 15-year chest wall recurrence rate for mastectomy patients without or with irradiation was 13% and 16%, respectively (RR: 1.45; p = 0.3965).
Survival after isolated local recurrence
There were 14 isolated in-breast and 15 chest wall recurrence. The median time to an in-breast recurrence was 47.5 months (mean, 59.9; range, 11-164 months). Thirteen of the fourteen patients with breast recurrence had invasive lobu- lar carcinoma as the histologic type of recurrence, and one had mucinous carcinoma. Breast recurrences were treated with mastectomy (n = 6) or tumor excision (n = 8). For five patients breast irradiation was given after tumor excision. Seven patients died of breast cancer (n = 6) or intercurrent disease (n = 1), and seven of them are alive with no evidence of disease. The breast cancer specific survival at 15 years was 74% without and 53% with ipsilateral breast tumor recurrence (RR, 1.73; 95% CI, 0.67-4.46; p, 0.2767).
The median time to a chest-wall recurrence was 30.0 months (mean, 36.1; range, 7-97 months). Surgery consisted of excision in 12 and incisional biopsy in 3 cases (multiplediffuse recurrence). 11 patients died of breast cancer and 4 are alive with no evidence of disease. The breast cancer-specific survival at 15 years was 66% without and 22% with local recurrence (RR, 2.65; 95% CI, 1.39-5.06; p, 0.0089).
Discussion
Nowadays mastectomy and breast conservation are offered as equally effective treatments for women with early-stage ILC. However, some doubts have been expressed about the choice of treatment because of poorer results published earlier and of the insidious nature of this disease. 1, [19] [20] [21] In this report, we documented our experience with ILC in a group of 235 women treated with either mastectomy or BCS who were monitored for a median of 181 months. The results of our study indicate that patients treated with mastectomy or BCS have a similar outcome at 15 years after initial surgery with regard to distant metastasis-free and breast cancer-specific survival. After irradiation, the actuarially estimated 15-year local recurrence rate in the breast or in the chest wall was 10% and 16%, respectively. There are at least four studies comparing the mastectomy with BCS for the treatment of ILC. [7] [8] [9] 20 Of these, only Anwar et al. 20 found that local recurrence rate was significantly higher in patients treated with tumor excision and RT. At a median follow-up time of 168 months, the crude rate of local recurrence for mastectomy or BCS patients was 13.4% and 34%, respectively. In the other three studies the crude rate of local recurrence ranged from 2.8% to 5.4% for BCS and RT, which was similar to the local recurrence rate (3-12%) for mastectomy, at a median follow-up time of 48-60 months.
There are only three studies in which ILC patients treated with BCS and RT were followed up for more than 120 months after surgery. [13] [14] [15] In these series the crude rate of local recurrence ranged from 8% to 15%. In our series the crude rate of local recurrence for irradiated BCS patients was 12%. 19 of our patients were treated with BCS alone and 10 of them (53%) developed local recurrence. In three other series, some patients were also not subjected to RT after BCS. In the study of Sastre-Garau et al. 12 the local recurrence rate was not reported for these patients. In the study of Nemoto et al. 21 the crude rate of local recurrence was 29% (4 of 14) at 48 months and in Holland et al. study 7 this rate was 13% (2 of 15), at a median follow-up time of 55 months. Information regarding local relapse rate after longer follow-up of ILC patients treated with BCS alone is not available. The NSABP B-06 randomized trial showed that after lumpectomy alone the cumulative incidence of breast recurrence was 53% at 10 years for all nonirradiated patients. 22 Our practice was that the patients with microscopically positive surgical margin undergo re-excision. At the first surgery, 11% of our cases had positive surgical margin, and after re-excision three of them underwent mastectomy. To obtain clear surgical margins, re-excision is also recommended by others. 23, 24 However, in the eighties the margins were evaluated without ink. The high numbers of in-breast failure in our nonirradiated patients indicate that tumor deposits may be left behind by primary surgery. One of the factors which increased the risk of residual disease after BCS is the insidious nature of ILC, characterized by small invasive "satellites" which appear in the 1-2 cm of otherwise uninvolved breast tissue beyond the margin of the principal tumor. 25 This phenomenon also underlines the mandatory use of RT to control microscopic residual disease and to achieve appropriate local control. In the study of van den Broek et al. 26 the risk of margin involvement was 29% after the first operation and 17% after re-excision, but there was no influence of the positive surgical margins on the risk of local recurrence after RT.
To our knowledge none of the studies compared the survival of patients with and without local recurrence in ILC. In our series, an isolated chest wall recurrence predicted significantly increased mortality (RR, 2.65; p, 0.0089) but in-breast recurrence did not (RR, 1.73; p, 0.2767). The prognosis following in-breast recurrence after BCS is much better than following chest-wall recurrence after mastectomy. 27 Patients treated with BCS and RT may be at persistent risk of breast failure even 10 years after initial surgery. 20, 28, 29 In our patients treated with BCS and RT, 2 of 4 in-breast recurrences occurred more than 10 years after treatment.
Conclusions
The results of this study indicate that patients with early-stage ILC subjected to mastectomy or BCS have a similar outcome after long-term follow-up with regard to distant metastasisfree and breast cancer-specific survival. BCS can provide a low local recurrence rate when RT is administered. The majority of ipsilateral in breast recurrences are but those of chest-wall recurrences are not curable.
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